GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Total Inventories

Bright Minds Biosciences (XCNQ:DRUG) Total Inventories : C$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Total Inventories?

Bright Minds Biosciences's total inventories for the quarter that ended in Dec. 2023 was C$0.00 Mil. Bright Minds Biosciences's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was C$0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Bright Minds Biosciences's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was C$1.32.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Bright Minds Biosciences Total Inventories Historical Data

The historical data trend for Bright Minds Biosciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Total Inventories Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Total Inventories
- - - -

Bright Minds Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bright Minds Biosciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Bright Minds Biosciences  (XCNQ:DRUG) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Bright Minds Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(6.762+0.75 * 0+0.5 * 0-0.854
-0-0)/4.46374
=1.32

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Bright Minds Biosciences's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Bright Minds Biosciences's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Bright Minds Biosciences's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Bright Minds Biosciences Total Inventories Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences (XCNQ:DRUG) Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Executives
Jeremy Fryzuk Director

Bright Minds Biosciences (XCNQ:DRUG) Headlines